Novo Nordisk aims to expand Rybelsus use for preventing cardiovascular events in T2D patients with CVD/CKD. The successful Phase III SOUL trial showed a 14% reduction in MACE risk.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
Novo Nordisk aims to expand Rybelsus use for preventing cardiovascular events in T2D patients with CVD/CKD. The successful Phase III SOUL trial showed a 14% reduction in MACE risk.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
We are preparing, please wait
This content is only available for premium members. Please become a paid member to access.
Download AppCurrently, memberships can only be purchased through the app.